BR0312002A - Composição para solubilização de paclitaxel e método de preparação da mesma - Google Patents

Composição para solubilização de paclitaxel e método de preparação da mesma

Info

Publication number
BR0312002A
BR0312002A BR0312002-3A BR0312002A BR0312002A BR 0312002 A BR0312002 A BR 0312002A BR 0312002 A BR0312002 A BR 0312002A BR 0312002 A BR0312002 A BR 0312002A
Authority
BR
Brazil
Prior art keywords
paclitaxel
composition
weight
preparation
present
Prior art date
Application number
BR0312002-3A
Other languages
English (en)
Other versions
BRPI0312002B1 (pt
Inventor
Hesson Chung
Seo-Young Jeong
Ick-Chan Kwon
Yeong-Taek Park
In-Hyun Lee
Soon-Hong Yuk
Young-Wook Choi
Jae-Hyung Park
Jin-Wook Chung
Original Assignee
Korea Inst Sci & Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36386602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0312002(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Korea Inst Sci & Tech filed Critical Korea Inst Sci & Tech
Publication of BR0312002A publication Critical patent/BR0312002A/pt
Publication of BRPI0312002B1 publication Critical patent/BRPI0312002B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçãO PARA SOLUBILIZAçãO DE PACLITAXEL E MéTODO DE PREPARAçãO DA MESMA". A presente invenção refere-se a uma composição de paclitaxel e aos métodos de preparação da mesma para solubilizar o paclitaxel onde a referida composição compreende 4-90% em peso de pelo menos um selecionado dos monoglicerídeos, 0,01-90% em peso de pelo menos um óleo e 0,01-20% em peso de paclitaxel. A presente invenção também refere-se a uma composição de paclitaxel incluindo emulsificantes e aos métodos de preparação da mesma para solubilizar o paclitaxel onde a referida composição compreende 4-90% em peso de pelo menos um selecionado dos monoglicerídeos, 0,01-90% em peso de pelo menos um óleo, 0,01-90% em peso de pelo menos um emulsificante e 0,01-20% em peso de paclitaxel. A composição da presente invenção é um sistema de distribuição de paclitaxel eficaz uma vez que a composição solubiliza o paclitaxel, não forma agregados depois ser dispersada em água, adsorve bem na parede intestinal, e portanto tem alta biodisponibilidade.
BRPI0312002-3A 2002-07-20 2003-07-18 Composition for solubilization of paclitaxel and method of preparing the same BRPI0312002B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2002-0042791 2002-07-20
KR10-2002-0042791A KR100533458B1 (ko) 2002-07-20 2002-07-20 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
PCT/KR2003/001427 WO2004009075A1 (en) 2002-07-20 2003-07-18 Composition for solubilization of paclitaxel and preparation method thereof

Publications (2)

Publication Number Publication Date
BR0312002A true BR0312002A (pt) 2005-05-03
BRPI0312002B1 BRPI0312002B1 (pt) 2017-11-28

Family

ID=36386602

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0312002A BRPI0312002B8 (pt) 2002-07-20 2003-07-18 composição para solubilização de paclitaxel e método de preparação da mesma
BRPI0312002-3A BRPI0312002B1 (pt) 2002-07-20 2003-07-18 Composition for solubilization of paclitaxel and method of preparing the same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0312002A BRPI0312002B8 (pt) 2002-07-20 2003-07-18 composição para solubilização de paclitaxel e método de preparação da mesma

Country Status (12)

Country Link
US (1) US8075917B2 (pt)
EP (1) EP1545499B1 (pt)
JP (1) JP4744875B2 (pt)
KR (1) KR100533458B1 (pt)
CN (1) CN100544714C (pt)
AU (1) AU2003281465A1 (pt)
BR (2) BRPI0312002B8 (pt)
CA (1) CA2493336C (pt)
HK (1) HK1082674A1 (pt)
RU (1) RU2291693C2 (pt)
WO (1) WO2004009075A1 (pt)
ZA (1) ZA200409126B (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375203B2 (en) 2002-03-25 2016-06-28 Kieran Murphy Llc Biopsy needle
US7927368B2 (en) * 2002-03-25 2011-04-19 Kieran Murphy Llc Device viewable under an imaging beam
US20030181810A1 (en) * 2002-03-25 2003-09-25 Murphy Kieran P. Kit for image guided surgical procedures
KR100533460B1 (ko) * 2002-07-20 2005-12-08 대화제약 주식회사 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법
US8178129B2 (en) 2004-11-02 2012-05-15 Tel-Aviv University Future Technology Development L.P. Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles and their use for diagnostic and therapy
EP1787645A1 (en) * 2005-11-18 2007-05-23 Institut Curie New method for treating cancer based on the modulation of the calcineurin and/or the calcineurin/NFAT pathway
KR100737742B1 (ko) * 2005-12-05 2007-07-10 대화제약 주식회사 파클리탁셀 조성물의 제조 방법
CN101006997B (zh) * 2006-01-26 2011-07-20 董英杰 复方紫杉醇及衍生物多西他赛脂肪乳剂和制备方法
JPWO2008041553A1 (ja) 2006-09-26 2010-02-04 アステラス製薬株式会社 タクロリムス徐放性製剤
EP2119442A4 (en) 2006-12-28 2010-12-15 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION WITH TACROLIMUS MAINTAINED RELEASE
WO2008098415A1 (fr) * 2007-02-14 2008-08-21 Beijing Century Biocom Pharmaceutical Technology Co., Ltd. Composition pharmaceutique contenant du taxane et son procédé de préparation et d'application
JP5135852B2 (ja) * 2007-03-30 2013-02-06 日油株式会社 可溶化用組成物
CA3039251C (en) 2008-11-10 2024-01-09 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
EP2204167A1 (en) 2009-01-05 2010-07-07 Azad Pharma AG Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
CN101785757B (zh) * 2009-01-22 2012-02-22 美迪思生物科技(北京)有限公司 一种紫杉醇自乳化制剂及其制备方法和用途
CN101926757B (zh) 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
JP6184943B2 (ja) * 2011-05-30 2017-08-23 オートテリック エルエルシー ポイント・オブ・ケア薬物動態プロフィールによる治療薬モニタリングおよび用量投与のための方法および組成物
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
JP6352258B2 (ja) * 2012-07-16 2018-07-04 センターズ フォー ディジーズ コントロール アンド プリベンション 抗腫瘍薬による表面汚染に対する直接読み取り検出キット
US9018246B2 (en) 2012-09-05 2015-04-28 Lp Pharmaceutical (Xiamen) Co., Ltd. Transmucosal administration of taxanes
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3174542A4 (en) 2014-07-29 2018-01-03 TherapeuticsMD, Inc. Transdermal cream
ES2524248B2 (es) * 2014-08-01 2015-07-03 Lvd Biotech S.L. Balón liberador de paclitaxel y procedimiento de fabricación del mismo
KR101542364B1 (ko) * 2014-10-31 2015-08-07 대화제약 주식회사 탁산을 포함하는 경구 투여용 약학 조성물
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR101612257B1 (ko) 2015-07-30 2016-04-20 대화제약 주식회사 고농도의 탁산을 포함하는 경구 투여용 약학 조성물
US10987335B2 (en) 2015-07-30 2021-04-27 Dae Hwa Pharma. Co., Ltd. Pharmaceutical composition for oral administration comprising high concentration taxane
RU2018113280A (ru) * 2015-09-16 2019-10-16 ДиЭфБи СОРИА, ЭлЭлСи Доставка наночастиц лекарственного средства и способы их использования
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
CA3026108A1 (en) 2016-06-10 2017-12-14 Clarity Cosmetics Inc. Non-comedogenic hair and scalp care formulations and method for use
CN106620717B (zh) * 2016-12-13 2020-11-24 上海交通大学 一种具有逆转肿瘤多药耐药性功能的两亲性缀合物抗肿瘤纳米药及其制备方法和应用
WO2018159941A1 (ko) * 2017-03-02 2018-09-07 대화제약 주식회사 자나미비르를 포함하는 안정한 약제학적 조성물
KR101991661B1 (ko) * 2017-03-02 2019-06-21 대화제약 주식회사 자나미비르를 포함하는 안정한 약제학적 조성물
EP3595633B1 (en) 2017-03-15 2023-07-05 DFB Soria, LLC Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
US11254773B2 (en) 2017-05-11 2022-02-22 The Regents Of The University Of California Nanoscale multiple emulsions and nanoparticles
WO2019159062A1 (en) 2018-02-13 2019-08-22 Murphy Kieran P Delivery system for delivering a drug depot to a target site under image guidance and methods and uses of same
CA3092500A1 (en) 2018-03-16 2019-09-19 Dfb Soria, Llc Topical therapy for the treatment of cervical intraepithelial neoplasia (cin) and cervical cancer using nanoparticles of taxanes
KR20200005110A (ko) * 2018-07-05 2020-01-15 대화제약 주식회사 탁산-함유 약학 조성물을 함유하는 의약품의 안정성 개선방법
KR102093100B1 (ko) * 2018-07-11 2020-03-26 대화제약 주식회사 산화 안정성이 향상된 탁산을 포함하는 경구용 약학 조성물
US11439586B2 (en) * 2018-10-16 2022-09-13 US Nano Food & Drug INC Intratumour injection formulation
CN109821055A (zh) * 2019-02-01 2019-05-31 厦门大学 一种药物-碘油溶剂及其制备方法
KR20200142943A (ko) * 2019-06-14 2020-12-23 대화제약 주식회사 항바이러스제를 포함하는 분말 제제 형태의 경구투여용 약학 조성물
KR102185475B1 (ko) 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물
CN110302434A (zh) * 2019-07-14 2019-10-08 大连医科大学 一种易于推注的碘化油栓塞剂及其制备方法
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN113244254B (zh) * 2021-03-26 2023-03-14 浙江工业大学 一种增强金黄霉素a水溶性的组合物及其制备与应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5618914A (en) * 1979-07-25 1981-02-23 Eisai Co Ltd Ubidecarenone composition having good absorbability
JPH0629180B2 (ja) * 1986-06-16 1994-04-20 エーザイ株式会社 吸収性の改良されたメナテトレノン含有組成物
CA2038744C (en) * 1990-03-23 2002-01-08 Yoshitomi Pharmaceutical Industries Ltd. Pharmaceutical composition containing slightly water-soluble drug
JPH06509577A (ja) * 1991-07-26 1994-10-27 スミスクライン・ビーチャム・コーポレイション Ｗ／ｏミクロエマルジョン
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
SI0999826T1 (en) * 1997-07-29 2004-12-31 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
AU728695B2 (en) * 1997-07-29 2001-01-18 Boehringer Ingelheim International Gmbh Self-emulsifying formulation for lipophilic compounds
WO1999049948A1 (en) * 1998-04-01 1999-10-07 Mattel, Inc. Toy vehicle jumpset with crossing rise and descent paths
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
IL146567A0 (en) * 1999-06-04 2002-07-25 Skyepharma Inc Oil-core particles containing a hydrophobic core material and hydrophobic drug and method for the preparation thereof
CN1174741C (zh) 1999-09-21 2004-11-10 Rtp药品公司 生物活性物质的表面改性微粒组合物
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
KR20030019327A (ko) * 2000-03-24 2003-03-06 아이박스 리서치 인코포레이티드 탁산-기저 조성물을 안정시키는 금속염의 용도
JP3448006B2 (ja) 2000-03-29 2003-09-16 独立行政法人食品総合研究所 機能性エマルション
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
KR20020013174A (ko) * 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
EP1365759A2 (en) * 2001-01-18 2003-12-03 PHARMACIA & UPJOHN COMPANY Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
WO2003053350A2 (en) 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
KR100573289B1 (ko) * 2002-07-20 2006-04-24 대화제약 주식회사 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법
KR100533460B1 (ko) * 2002-07-20 2005-12-08 대화제약 주식회사 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법

Also Published As

Publication number Publication date
JP4744875B2 (ja) 2011-08-10
ZA200409126B (en) 2005-06-29
EP1545499A1 (en) 2005-06-29
HK1082674A1 (en) 2006-06-16
WO2004009075A1 (en) 2004-01-29
US20060104999A1 (en) 2006-05-18
BRPI0312002B8 (pt) 2022-10-18
EP1545499A4 (en) 2009-11-18
CA2493336C (en) 2009-11-24
CA2493336A1 (en) 2004-01-29
RU2291693C2 (ru) 2007-01-20
CN1671370A (zh) 2005-09-21
KR100533458B1 (ko) 2005-12-07
KR20040009015A (ko) 2004-01-31
JP2005538090A (ja) 2005-12-15
BRPI0312002B1 (pt) 2017-11-28
US8075917B2 (en) 2011-12-13
AU2003281465A1 (en) 2004-02-09
RU2005104567A (ru) 2005-07-10
CN100544714C (zh) 2009-09-30
EP1545499B1 (en) 2013-02-20

Similar Documents

Publication Publication Date Title
BR0312002A (pt) Composição para solubilização de paclitaxel e método de preparação da mesma
Qureshi et al. Novel tocotrienols of rice bran inhibit atherosclerotic lesions in C57BL/6 ApoE-deficient mice
BR9916063A (pt) Composições auto-emulsificantes para medicamentos fracamente solúveis em água
CY1111471T1 (el) Μεθοδοι για τον καθαρισμο trans-(-)-δ9-τετραϋδροκανναβινολης και trans-(+)-δ9 τετραϋδροκανναβινολης
BR0307524A (pt) Composição farmacêutica para inibidores de protease viral de hepatite c
AR063555A1 (es) Derivados de androstano, su uso en la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden y procesos para prepararlos
BRPI0517313A (pt) composição contendo óleo, artigo de consumo, método para conferir, intensificar, melhorar ou modificar propriedades, processo para a preparação de uma composição, e, sistema para a solubilização de óleo
BRPI0605831A (pt) composição de revestimento de polìmero de emulsão de baixo teor de voc
ECSP034620A (es) Mezclas o compuestos organicos para el tratamiento de enfermedades de las vias respiratorias
SI2168585T1 (sl) Farmacevtski sestavki nevroaktivnega steroida in njihove uporabe
DK1390039T3 (da) Anvendelse af östrogenforbindelser til forögelse af kvinders libido
RS50972B (sr) Farmaceutski sastav koji sadrži gestagene i/ili estrogene i 5-metil-(6s)-tetrahidrofolate
ATE367810T1 (de) Zusammensetzung zur prävention von osteoporose bestehend aus einer kombination aus isoflavonen und polyungesättigten fettsäuren
DE502005006701D1 (de) Triterpenhaltiger oleogelbildner, triterpenhaltiges oleogel und verfahren zur herstellung eines triterpenhaltigen oleogels
DE60204712D1 (de) Zubereitung enthaltend paracetamol und ein geschmacksmaskierungsmittel
BRPI0608061A2 (pt) método para abaixar os nìveis no sangue circulante de um lipìdio selecionado do grupo que consiste em colesterol ldl, triglicerìdios, colesterol total, e as misturas destes e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons
Burlet et al. Strontium ranelate: the first dual acting treatment for postmenopausal osteoporosis
BRPI0409413A (pt) composição farmacêutica, uso de um ácido ou sal biliar não conjugado, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um pacinete e para tratar um paciente que esteja sofrendo de uma condição ou doença tratável
BR0116179A (pt) Composição despejável, processo de preparação de uma composição despejável e uso da composição
EA200200217A1 (ru) Парентеральная цисплатиновая эмульсия
BR0108718A (pt) Veìculo lipìdico
Hunneyball et al. Pharmacological studies of antigen-induced arthritis in BALB/c mice II. The effects of second-line antirheumatic drugs and cytotoxic agents on the histopathological changes
AR062200A1 (es) Derivados de antraceno y su uso para el tratamiento de emfermedades tumorales bengnas y malingnas
TW200608902A (en) Coagulating agent for water-in-oil type emulsifying type soybean curd
BR0312817A (pt) Composição de pomada oftálmica compreendendo uma droga, uma base de pomada e um agente solubilizante/dispersante

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: DAEHWA PHARM. CO., LTD. (KR)

Free format text: TRANSFERIDO DE: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PARA: INT. CL. A61K 31/337

Ipc: A61K 31/337 (2011.01), A61P 35/00 (2011.01)

Free format text: PARA: INT. CL. A61K 31/337; A61P 35/00

Ipc: A61K 31/337 (2011.01), A61P 35/00 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/07/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2447 DE 28/11/2017 QUANTO AO RELATORIO DESCRITIVO.